Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This month symbols : Bmy save search
Pomerantz Law Firm Announces the Filing of a Class Action Against VinFast Auto Ltd. and Certain Officers - VFS
Published: 2024-04-12 (Crawled : 20:00) - prnewswire.com
FICO S | $1130.06 -2.77% 0.0% 140K
|
Technology Services
| Email alert
Add to watchlist
VFS | News | $2.51 -7.38% -7.97% 5.6M
|
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
BSAQ | News | $10.2 2.45% 380
|
| Email alert
Add to watchlist
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.25%
H: 1.1%
C: -0.17%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.05%
H: 0.43%
C: -0.27%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -0.35%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.18%
H: 0.3%
C: 0.19%
eczema dermatitis set therapeutics market
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.52 -2.59% -2.65% 610K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.08%
H: 0.3%
C: -0.99%
reblozyl anemia approval treatment
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.21%
H: 0.47%
C: -0.68%
report
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.